Filters
Filter
Custom request?
Type
Production region
Qualifications
Country of origin
Olaparib API Manufacturers & Suppliers
9 verified results
Get full market intelligence report
All Olaparib data. Full access. Full negotiation power
€399,-
Commercial-scale Suppliers
Producer
Produced in
China|
Employees: 300+
|
Audit Report:
Certifications:
GMP
|
MSDS|
BSE/TSE|
CoAAll certificates
GMP
MSDS
BSE/TSE
CoA
Producer
Produced in
China|
Audit Report:
Certifications:
MSDS
|
ISO9001|
CoAAll certificates
MSDS
ISO9001
CoA
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Distributor
Produced in
India|
Employees: 25
|
Audit Report:
Certifications:
GMP
|
FDA|
MSDS|
BSE/TSE|
ISO9001All certificates
GMP
FDA
MSDS
BSE/TSE
ISO9001
CoA
Producer
Produced in
Czech Republic|
Audit Report:
Certifications:
CoA
All certificates
CoA
Distributor
Produced in
China|
Employees: 50+
|
Audit Report:
Certifications:
CoA
All certificates
CoA
Producer
Produced in
China|
Employees: 500
|
Audit Report:
Certifications:
MSDS
|
BSE/TSE|
CoAAll certificates
MSDS
BSE/TSE
CoA
Get full market intelligence report
€399,-
All Olaparib data. Full access. Full negotiation power
Producer
Produced in
China|
Audit Report:
Certifications:
USDMF
|
CoAAll certificates
USDMF
CoA
Producer
Produced in
India|
Employees: 21,650
|
Audit Report:
Certifications:
GMP
|
FDA|
USDMF|
MSDS|
BSE/TSEAll certificates
GMP
FDA
USDMF
MSDS
BSE/TSE
WC
CoA
Take control of your API sourcing
Producer
Produced in
China|
Audit Report:
Certifications:
coa
All certificates
coa
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency
|
Supplier trade data access
|
Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Olaparib | CAS No: 763113-22-0 | GMP-certified suppliers
A medication that supports treatment and maintenance of BRCA‑associated ovarian, breast, pancreatic, and prostate cancers to help manage advanced or recurrent disease across key oncology settings.
Therapeutic categories
Antineoplastic AgentsAntineoplastic and Immunomodulating AgentsBCRP/ABCG2 InhibitorsCytochrome P-450 CYP2B6 InducersCytochrome P-450 CYP2B6 Inducers (strength unknown)Cytochrome P-450 CYP3A Inducers
Generic name
Olaparib
Molecule type
small molecule
CAS number
763113-22-0
DrugBank ID
DB09074
Approval status
Approved drug
ATC code
L01XK01
Primary indications
- Ovarian cancer**
- Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy
- Olaparib is indicated in combination with [bevacizumab] for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability
Product Snapshot
- Olaparib is an oral small-molecule PARP inhibitor supplied as capsules and film‑coated tablets
- It is used for maintenance or treatment settings across BRCA‑ or HRR‑associated ovarian, breast, pancreatic, and metastatic castration‑resistant prostate cancers
- It holds approved status in major regulated markets including the US, Canada, and the EU
Clinical Overview
Olaparib (CAS 763113-22-0) is an orally administered inhibitor of poly(ADP‑ribose) polymerase enzymes, primarily PARP1 and PARP2. It is used for the treatment or maintenance treatment of several BRCA‑associated or homologous recombination repair–deficient malignancies, including epithelial ovarian, fallopian tube, primary peritoneal, breast, pancreatic, and prostate cancers. Approved uses include monotherapy and defined combinations with bevacizumab or with abiraterone plus prednisone or prednisolone, depending on tumour type and mutation status.
Olaparib exerts antitumour activity by blocking PARP‑mediated DNA repair. Inhibition of the base excision repair pathway leads to accumulation of single‑strand DNA breaks and secondary double‑strand breaks. Cells with intact BRCA‑dependent homologous recombination can repair these lesions, whereas tumours with BRCA1/2 or other homologous recombination repair defects accumulate lethal DNA damage. This synthetic lethality underpins its selectivity for HR‑deficient tumour cells. In vitro and in vivo xenograft models show activity as monotherapy and in combination with DNA‑damaging agents or radiotherapy.
Absorption is adequate following oral dosing, and the compound is metabolized primarily via CYP3A pathways. Olaparib is also a substrate or inhibitor of several transporters, including P‑glycoprotein, BCRP, OATP1B1, OAT3, and MATE proteins. These properties contribute to a meaningful interaction potential with strong or moderate CYP3A inhibitors or inducers and with transporter substrates. Elimination is through metabolic clearance with urinary and fecal excretion.
The safety profile is characterized by myelosuppression, gastrointestinal events, fatigue, and increased risks of pneumonitis and secondary malignancies such as myelodysplastic syndrome or acute myeloid leukemia. Dose adjustments or treatment interruption may be required for hematologic toxicity.
Common global brands include Lynparza. For API sourcing, suppliers should demonstrate control of stereochemistry and related phthalazinone impurities, maintain consistency in particle size distribution for oral formulation performance, and provide full regulatory documentation supporting GMP compliance and impurity characterization.
Olaparib exerts antitumour activity by blocking PARP‑mediated DNA repair. Inhibition of the base excision repair pathway leads to accumulation of single‑strand DNA breaks and secondary double‑strand breaks. Cells with intact BRCA‑dependent homologous recombination can repair these lesions, whereas tumours with BRCA1/2 or other homologous recombination repair defects accumulate lethal DNA damage. This synthetic lethality underpins its selectivity for HR‑deficient tumour cells. In vitro and in vivo xenograft models show activity as monotherapy and in combination with DNA‑damaging agents or radiotherapy.
Absorption is adequate following oral dosing, and the compound is metabolized primarily via CYP3A pathways. Olaparib is also a substrate or inhibitor of several transporters, including P‑glycoprotein, BCRP, OATP1B1, OAT3, and MATE proteins. These properties contribute to a meaningful interaction potential with strong or moderate CYP3A inhibitors or inducers and with transporter substrates. Elimination is through metabolic clearance with urinary and fecal excretion.
The safety profile is characterized by myelosuppression, gastrointestinal events, fatigue, and increased risks of pneumonitis and secondary malignancies such as myelodysplastic syndrome or acute myeloid leukemia. Dose adjustments or treatment interruption may be required for hematologic toxicity.
Common global brands include Lynparza. For API sourcing, suppliers should demonstrate control of stereochemistry and related phthalazinone impurities, maintain consistency in particle size distribution for oral formulation performance, and provide full regulatory documentation supporting GMP compliance and impurity characterization.
Identification & chemistry
| Generic name | Olaparib |
|---|---|
| Molecule type | Small molecule |
| CAS | 763113-22-0 |
| UNII | WOH1JD9AR8 |
| DrugBank ID | DB09074 |
Pharmacology
| Summary | Olaparib is a PARP1/2‑selective inhibitor that disrupts NAD+-dependent DNA repair pathways, leading to accumulation of single‑strand and double‑strand breaks. Cells with deficiencies in homologous recombination repair, such as those with BRCA1/2 mutations, are particularly susceptible to this induced genomic instability. The resulting synthetic lethality underpins its antitumor activity across multiple preclinical cancer models. |
|---|---|
| Mechanism of action | Poly(ADP-ribose) polymerases (PARPs) are multifunctional enzymes comprising 17 members. They are involved in essential cellular functions, such as DNA transcription and DNA repair.PARPs recognize and repair cellular DNA damage, such as single-strand breaks (SSBs) and double-strand breaks (DSBs). Different DNA repair pathways exist to repair these DNA damages, including the base excision repair (BER) pathway for SSBs and BRCA-dependent homologous recombination for DSBs. Olaparib is a PARP inhibitor: while it acts on PARP1, PARP2, and PARP3, olaparib is a more selective competitive inhibitor of NAD<sup>+</sup> at the catalytic site of PARP1 and PARP2. Inhibition of the BER pathway by olaparib leads to the accumulation of unrepaired SSBs, which leads to the formation of DSBs, which is the most toxic form of DNA damage. While BRCA-dependent homologous recombination can repair DSBs in normal cells, this repair pathway is defective in cells with BRCA1/2 mutations, such as certain tumour cells.Inhibition of PARP in cancer cells with BRCA mutations leads to genomic instability and apoptotic cell death. This end result is also referred to as synthetic lethality, a phenomenon where the combination of two defects - inhibition of PARP activity and loss of DSB repair by HR - that are otherwise benign when alone, lead to detrimental results. _In vitro_ studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death. |
| Pharmacodynamics | Olaparib is a cytotoxic and anti-tumour agent. Olaparib inhibits the growth of selective tumour cell lines _in vitro_ and decreases tumour growth in mouse xenograft models of human cancer, both as monotherapy or following platinum-based chemotherapy. The drug exerts anti-tumour effects in cell lines and mouse tumour models with deficiencies in BRCA1/2, ATM, or other genes involved in the homologous recombination repair (HRR) of DNA damage and correlated with platinum response. In preclinical models of cancer, olaparib demonstrated anti-tumour activity when used alone, in combination with chemotherapeutic agents, or radiotherapy.Olaparib can act as a chemosensitizer to potentiate the cytotoxicity of DNA-damaging chemotherapeutic agents such as alkylating agents and platinum-based drugs. It can also act as a radiosensitizer by preventing PARP-mediated DNA repair. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Poly [ADP-ribose] polymerase 1 | Humans | inhibitor |
| Poly [ADP-ribose] polymerase 2 | Humans | inhibitor |
| Poly [ADP-ribose] polymerase 3 | Humans | inhibitor |
ADME / PK
| Absorption | Following oral administration, olaparib is rapidly absorbed.After administration of a single 300 mg dose of olaparib, the mean (CV%) C<sub>max</sub> was 5.4 μg/mL (32%) and AUC was 39.2 μg x h/mL (44%). The steady state C<sub>max</sub> and AUC following a dose of 300 mg twice daily was 7.6 μg/mL (35%) and 49.2 μg x h/mL (44%), respectively. T<sub>max</sub> is 1.5 hours. A high-fat and high-calorie meal may delay T<sub>max</sub>, but does not significantly alter the extent of olaparib absorption. |
|---|---|
| Half-life | Following a single oral dose in patients with cancer, the mean terminal half-life was 6.10 hours. |
| Protein binding | The protein binding of olaparib is approximately 82% _in vitro_.In solutions of purified proteins, the olaparib fraction bound to albumin was approximately 56% and the fraction bound to alpha-1 acid glycoprotein was 29%. |
| Metabolism | Olaparib is metabolized by cytochrome P450 (CYP) 3A4/5 _in vitro_. Following an oral dose of radiolabeled olaparib to female patients, unchanged olaparib accounted for 70% of the circulating radioactivity in plasma. Olaparib undergoes oxidation reactions as well as subsequent glucuronide or sulfate conjugation.In humans, olaparib can also undergo hydrolysis, hydroxylation, and dehydrogenation. While up to 37 metabolites of olaparib were detected in plasma, urine, and feces, the majority of metabolites represent less than 1% of the total administered dose and they have not been fully characterized. The major circulating metabolites are a ring-opened piperazin-3-ol moiety and two mono-oxygenated metabolites. The pharmacodynamic activity of the metabolites is unknown. |
| Route of elimination | Following a single dose of radiolabeled olaparib, 86% of the dosed radioactivity was recovered within a seven-day collection period, mostly in the form of metabolites. About 44% of the drug was excreted via the urine and 42% of the dose was excreted via the feces. Following an oral dose of radiolabeled olaparib to female patients, the unchanged drug accounted for 15% and 6% of the radioactivity in urine and feces, respectively. |
| Volume of distribution | The mean (± standard deviation) apparent volume of distribution of olaparib is 158 ± 136 L following a single 300 mg dose. |
| Clearance | Following a single oral dose in patients with cancer, the mean apparent plasma clearance was 4.55 L/h. |
Formulation & handling
- Oral small‑molecule API with low aqueous solubility, often requiring solubility‑enhancing or solid‑dispersion approaches for consistent exposure.
- Stable as a solid; typical tablet and capsule formulations use protective coatings to manage moisture and improve manufacturability.
- Absorption is food‑independent, allowing flexible oral formulation without fed‑state performance constraints.
Regulatory status
| Lifecycle | The API shows a mixed patent landscape, with several US protections expiring between 2024 and 2028 and one extending to 2031, indicating a transition from mid‑ to late‑lifecycle status. With products already marketed in the US, Canada, and the EU, the market is maturing as early patents expire while a later-expiring patent maintains some remaining exclusivity. |
|---|
| Markets | US, Canada, EU |
|---|
Supply Chain
| Supply chain summary | Olaparib is produced by a single originator company that supplies branded product across major regulated markets, including the United States, Canada, and the European Union. The branded formulation has broad global presence, with Lynparza as the reference product. Several U.S. patents have recently expired or are nearing expiry, while others extend to 2027–2031, indicating that some jurisdictions may see emerging generic interest as protections phase out, while others remain patent‑protected. |
|---|
Safety
| Toxicity | The oral LD<sub>50</sub> in rats is approximately 240-300 mg/kg. There is limited information regarding the overdose of olaparib. |
|---|
High Level Warnings:
- Rat oral LD50 is approximately 240–300 mg/kg, indicating moderate acute toxicity and the need for controlled handling to limit exposure
- Limited overdose data are available
- However, the compound’s mechanism suggests potential for dose‑related hematologic and gastrointestinal adverse effects
Olaparib is a type of Protein kinase inhibitors
Protein kinase inhibitors are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in targeted cancer therapies. These inhibitors specifically target and block the activity of protein kinases, enzymes that regulate various cellular processes, including cell growth, division, and signal transduction.
Protein kinase inhibitors function by binding to the active site of protein kinases, preventing them from phosphorylating specific proteins and disrupting intracellular signaling pathways. This targeted approach inhibits the uncontrolled growth and proliferation of cancer cells, ultimately leading to their death.
The development of protein kinase inhibitors has revolutionized cancer treatment by providing more effective and less toxic alternatives to traditional chemotherapy. These drugs have demonstrated impressive results in the treatment of various cancers, including lung, breast, and leukemia.
The pharmaceutical industry invests heavily in research and development to discover novel protein kinase inhibitors with improved potency, selectivity, and pharmacokinetic properties. High-throughput screening, computational modeling, and structure-activity relationship studies are employed to identify potential lead compounds.
The success of protein kinase inhibitors in treating cancer has spurred significant interest in this subcategory of APIs. Ongoing research aims to expand their applications to other diseases, such as autoimmune disorders and neurological conditions.
In conclusion, protein kinase inhibitors are a valuable class of pharmaceutical APIs with immense potential for targeted cancer therapies. Continued advancements in this field hold promise for improved treatment outcomes and enhanced patient care.
Olaparib (Protein kinase inhibitors), classified under Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
Olaparib API manufacturers & distributors
Compare qualified Olaparib API suppliers worldwide. We currently have 9 companies offering Olaparib API, with manufacturing taking place in 3 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| ALP PHARM | Producer | China | China | CoA, USDMF | 33 products |
| Chongqing Sintaho Pharmac... | Producer | China | China | CoA, ISO9001, MSDS | 42 products |
| Dr. Reddy's | Producer | India | India | BSE/TSE, CoA, FDA, GMP, MSDS, USDMF, WC | 170 products |
| Global Pharma Tek | Distributor | India | India | BSE/TSE, CoA, FDA, GMP, ISO9001, MSDS | 484 products |
| Hunan Ouya Biological Co.... | Producer | China | China | CoA | 7 products |
| Shandong Boyuan | Producer | China | China | BSE/TSE, CoA, MSDS | 55 products |
| Sinoway industrial Co.,Lt... | Distributor | China | China | CoA | 762 products |
| Tianjin Pharmacn Medical ... | Producer | China | China | BSE/TSE, CoA, GMP, MSDS | 66 products |
| Veeprho Group | Producer | Czech Republic | Czech Republic | CoA | 140 products |
When sending a request, specify which Olaparib API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Olaparib API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
Frequently asked questions about Olaparib API
Sourcing
What matters most when sourcing GMP-grade Olaparib?
The key factors are verifying GMP compliance and ensuring the material aligns with regulatory expectations in the United States, Canada, and the European Union. Because Olaparib is supplied by a single originator with ongoing patent coverage in several jurisdictions, confirming lawful sourcing and patent status is essential. It is also important to obtain full quality documentation from the supplier to support regulatory submissions.
Which documents are typically required when sourcing Olaparib API?
Request the core API documentation set: CoA (8 companies), MSDS (5 companies), BSE/TSE (4 companies), GMP (3 companies), USDMF (2 companies). Confirm versions and validity dates match the destination market to avoid delays in qualification.
Which manufacturers are known to produce Olaparib API?
Known or reported manufacturers for Olaparib: Tianjin Pharmacn Medical Technology Co., ltd, Global Pharma Tek, Chongqing Sintaho Pharmaceutical Co., Ltd., Sinoway industrial Co.,Ltd, Shandong Boyuan. Evaluate their GMP history, scale, and regional coverage before requesting dossiers or allocating demand.
How can I request quotes for Olaparib API from GMP suppliers?
Submit quote requests through the supplier listings with your specs and required documents (specifications, target volume, delivery timeline, and destination). Providing consistent details upfront speeds comparable offers and clarifies technical feasibility.
Is a GMP audit report available for Olaparib manufacturers?
Audit reports may be requested for Olaparib: 2 GMP audit reports available. Confirm the scope and recency of any audit before relying on it for qualification decisions.
How many suppliers offer Olaparib API on Pharmaoffer?
Reported supplier count for Olaparib: 8 verified suppliers. Filter listings by certifications, regions, and delivery options to match your qualification plan.
Which countries are known to manufacture Olaparib API?
Production countries reported for Olaparib: China (6 producers), India (2 producers). Knowing the manufacturing geography helps anticipate logistics lead times and import compliance needs.
Which certifications do suppliers of Olaparib usually hold?
Common certifications for Olaparib suppliers: CoA (8 companies), MSDS (5 companies), BSE/TSE (4 companies), GMP (3 companies), USDMF (2 companies). Always verify issuing authorities and expiry dates when reviewing audit packages.
Technical
What is Olaparib (CAS 763113-22-0) used for?
Olaparib is used to treat or maintain treatment of BRCA‑associated or homologous‑recombination–deficient cancers, including epithelial ovarian, fallopian tube, primary peritoneal, breast, pancreatic, and prostate malignancies. It is given as monotherapy or in defined combinations such as with bevacizumab or with abiraterone plus prednisone or prednisolone, depending on tumour type and mutation status. Its use targets tumours with impaired DNA repair, where PARP inhibition induces lethal DNA damage.
Which therapeutic class does Olaparib fall into?
Olaparib belongs to the following therapeutic categories: Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown). This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.
What conditions is Olaparib mainly prescribed for?
The primary indications for Olaparib: Ovarian cancer**, Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy, Olaparib is indicated in combination with [bevacizumab] for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.
How does Olaparib work?
Poly(ADP-ribose) polymerases (PARPs) are multifunctional enzymes comprising 17 members. They are involved in essential cellular functions, such as DNA transcription and DNA repair.PARPs recognize and repair cellular DNA damage, such as single-strand breaks (SSBs) and double-strand breaks (DSBs). Different DNA repair pathways exist to repair these DNA damages, including the base excision repair (BER) pathway for SSBs and BRCA-dependent homologous recombination for DSBs.
Olaparib is a PARP inhibitor: while it acts on PARP1, PARP2, and PARP3, Olaparib is a more selective competitive inhibitor of NAD+ at the catalytic site of PARP1 and PARP2. Inhibition of the BER pathway by Olaparib leads to the accumulation of unrepaired SSBs, which leads to the formation of DSBs, which is the most toxic form of DNA damage. While BRCA-dependent homologous recombination can repair DSBs in normal cells, this repair pathway is defective in cells with BRCA1/2 mutations, such as certain tumour cells.Inhibition of PARP in cancer cells with BRCA mutations leads to genomic instability and apoptotic cell death. This end result is also referred to as synthetic lethality, a phenomenon where the combination of two defects - inhibition of PARP activity and loss of DSB repair by HR - that are otherwise benign when alone, lead to detrimental results.
_In vitro_ studies have shown that Olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death.
What should someone know about the safety or toxicity profile of Olaparib?
Olaparib has a moderate acute toxicity in animals, with a rat oral LD50 of about 240–300 mg/kg, supporting the need for controlled handling. Its mechanism can produce dose‑related myelosuppression and gastrointestinal effects, and clinical use is associated with fatigue, pneumonitis, and rare cases of myelodysplastic syndrome or acute myeloid leukemia. Hematologic toxicity may require dose adjustment or treatment interruption. Limited information is available on overdose.
What are important formulation and handling considerations for Olaparib as an API?
Important considerations include its low aqueous solubility, which often necessitates solubility‑enhancing approaches such as solid dispersions to achieve consistent oral exposure. The API is stable as a solid but typically requires moisture‑protective excipients or coatings to support manufacturability. Food does not significantly affect overall absorption, allowing formulation without specific fed‑state performance requirements. Routine handling focuses on controlling moisture and ensuring uniform dispersion in the final dosage form.
Is Olaparib a small molecule?
Olaparib is classified as a small molecule. That classification shapes process design, impurity profiling, and analytical control strategies.
Are there special stability concerns for oral Olaparib?
Olaparib is stable as a solid but has low aqueous solubility, so oral formulations typically use solubility‑enhancing or solid‑dispersion technologies to maintain consistent exposure. Moisture sensitivity is managed with protective tablet or capsule coatings. Its absorption is food‑independent, so there are no special fed‑state stability concerns for the oral product.
Regulatory
Where is Olaparib approved or in use globally?
Olaparib is reported as approved in the following major regions: US, Canada, EU. Understanding geographic coverage informs regulatory filings, supply planning, and risk assessments before escalating procurement.
What’s the regulatory and patent landscape for Olaparib right now?
Olaparib is authorized for use in the United States, Canada, and the European Union. Its regulatory status in these regions includes established approvals for defined indications and labeling. Patent protections and exclusivities remain in place but vary by jurisdiction, with timelines governed by local intellectual‑property and regulatory frameworks.
Pharmaoffer
How does Pharmaoffer’s Smart Sourcing Service help with Olaparib procurement?
Pharmaoffer's Smart Sourcing Service coordinates compliant suppliers, documentation, and competitive quotes for Olaparib. It centralizes outreach, follow-ups, and document validation to shorten procurement timelines.
Is Olaparib included in the PRO Data Insights coverage?
PRO Data Insights coverage for Olaparib: 310 verified transactions across 96 suppliers and 63 buyers worldwide. Use the dataset to benchmark suppliers and monitor regulatory activity where available.
Where can I access the API market report for Olaparib?
Market report availability for Olaparib: Report Available. The report highlights demand trends, pricing drivers, and supplier landscape insights for procurement planning.
